Effect of Intensive Compared with Moderate Lipid-Lowering Therapy on Progression of Coronary Atherosclerosis (REVERSAL Trial)

The REVERSAL (Reversal of Atherosclerosis with Aggressive Lipid Lowering) trial randomized 502 patients with established CAD to intensive statin therapy (atorvastatin 80 mg, achieving median LDL-C of 79 mg/dL) or moderate statin therapy (pravastatin 40 mg, median LDL-C 110 mg/dL), tracking coronary atheroma by serial IVUS over 18 months.

Moderate-intensity statin therapy (pravastatin) did not halt plaque progression — atheroma volume increased, though modestly. Intensive statin therapy (atorvastatin) halted plaque progression, with no net change in atheroma volume. The difference between arms was statistically significant. Intensive therapy also produced greater reductions in LDL-C, CRP, and triglycerides, and greater HDL-C increases.

REVERSAL was the first trial to demonstrate that atherosclerosis progression could be halted — not just slowed — by aggressive LDL-C reduction with high-intensity statins. This was a conceptual advance: it established that halting versus slowing versus reversing atherosclerosis are different achievable targets depending on the intensity of therapy, and that the then-standard-of-care (pravastatin 40 mg) was insufficient to stop progression.

The REVERSAL results directly informed the landmark PROVE-IT trial and set the stage for subsequent IVUS trials demonstrating plaque regression with evolocumab (GLAGOV) and high-dose rosuvastatin (ASTEROID).

We rate the evidence strong. A seminal IVUS trial establishing that intensive statin therapy halts coronary plaque progression where moderate therapy cannot — a foundational justification for high-intensity statin use in established CAD.